Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
RHÖN-KLINIKUM AG is a German healthcare provider operating five hospital sites: Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen, Universitätsklinikum Marburg (UKGM), and Zentralklinik Bad Berka. The company offers inpatient and outpatient medical services, treating approximately 913,000 patients annually. Headquartered in Bad Neustadt a. d. Saale, Germany, RHÖN-KLINIKUM AG employs over 18,700 individuals. In 2020, Asklepios Kliniken GmbH & Co. KGaA acquired a majority stake in RHÖN-KLINIKUM AG, leading to a strategic partnership while maintaining RHÖN-KLINIKUM AG's independence within the Asklepios group. The company focuses on cross-sector healthcare delivery, digital transformation, and sustainability initiatives, including plans to achieve CO₂-neutrality in Scope 1 and Scope 2 emissions by 2040.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
View stock

Stock highlights

Stock comparison highlights
Stock name
RHÖN-KLINIKUM AktiengesellschaftAbbVie
Last price
€14.50$294.45
Currency
EUR
USD
€977M$521B
23.2950.79
€0.62$5.81
-0.19
€0.20$6.83
1.37%2.35%
Sector
HealthHealth
Employees
19,12057,000
Ticker
€RHK$ABBV
Primary listing
XETRANYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €RHK or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.